Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
ConclusionsPCSK-9 inhibitors are effective in reducing LDL cholesterol and the incidence of major cardiovascular events in high-risk patients. Bococizumab does not show significant effects on MACE.Registration numberPROSPERO-CRD42018087640.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Endocrinology | Heart | Statin Therapy | Study | Vytorin | Zetia